[Results of human immunization with a new rabies vaccine containing no neuroallergenic brain tissue factor].
Immunization with a vaccine prepared from sheep-brain-grown fixed rabies virus inactivated with beta-propiolactone was given to 146 subjects. The vaccine was by 80-90% purified from waste brain tissue substances (protein content less than 2 mg/ml) and showed no neuroallergenicity in guinea pig tests. Simultaneously 86 subjects were vaccinated with commercial Fermi vaccine. Immunization was performed according to the schedules accepted in the USSR. The new vaccine produced much fewer local reactions than Fermi vaccine (in 39.6% and 60.9% vaccinees, respectively) and 5 times as few systemic reactions (in 6.03% and 31.3% vaccinees, respectively). The antigenic potency of the new vaccine was as good as that of Fermi vaccine.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D000485:Allergens / Q000276:immunology*; D000914:Antibodies, Viral / Q000032:analysis; D001921:Brain / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007114:Immunization / Q000379:methods; D008875:Middle Aged; D009500:Neutralization Tests; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology; D013997:Time Factors
D000485:Allergens; D000914:Antibodies, Viral; D011819:Rabies Vaccines
Rezul'taty immunizatsii liudeĭ novoĭ antirabicheskoĭ vaktsinoĭ, ne soderzhascheĭ neĭroallergennogo faktora mozgovoĭ tkani.